《FDA无菌原料药制造商检查指南.doc》由会员分享，可在线阅读，更多相关《FDA无菌原料药制造商检查指南.doc（11页珍藏版）》请在金锄头文库上搜索。
1、GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERSNote: This document is reference material for investigators and other FDA personnel. The document does not bind FDA, and does no confer any rights, privileges, benefits, or immunities for or on any person(s). One of the more difficult proce
2、sses to inspect and one which has presented considerable problems over the years is that of the manufacture of sterile bulk drug substances. Within the past several years, there have been a number of batches of sterile bulk drug substances from different manufacturers which exhibited microbiological
3、 contamination. One manufacturer had approximately 100 batches contaminated in a 6 month time period. Another had approximately 25 batches contaminated in a similar period. Other manufacturers have had recalls due to the lack of assurance of sterility. Although the Inspection Guide for Bulk Drug Sub
4、stances provides some direction for the inspection of the sterile bulk drug substance, it does not provide the detailed direction needed.I. INTRODUCTIONIn the manufacture of the sterile bulk powders, it is important to recognize that there is no further processing of the finished sterile bulk powder
5、 to remove contaminants or impurities such as particulates, endotoxins and degradants.As with other inspections, any rejected batches, along with the various reasons for rejection, should be identified early in the inspection to provide direction for the investigator. For example, lists of batches r
6、ejected and/or retested over a period of time should be obtained from the manufacturer to provide direction for coverage to be given to specific processes or systems. Because some of the actual sterile bulk operations may not be seen, and because of the complexity of the process, it is particularly
7、important to review reports and summaries, such as validation studies, reject lists, Environmental Monitoring Summary Reports, QA Investigation Logs, etc. These systems and others are discussed in the Basic Inspection Guide. This is particularly important for the foreign sterile bulk drug substance
8、manufacturer where time is limited.In the preparation for a sterile bulk drug substance inspection, a flow chart with the major processing steps should be obtained. Generally, the manufacture of a sterile bulk substance usually includes the following steps:1. Conversion of the non-sterile drug subst
9、ance to the sterile form by dissolving in a solvent, sterilization of the solution by filtration and collection in a sterilized reactor (crystallizer).2. Aseptic precipitation or crystallization of the sterile drug substance in the sterile reactor.3. Aseptic isolation of the sterile substance by cen
10、trifugation or filtration.4. Aseptic drying, milling and blending of the sterile substance.5. Aseptic sampling and packaging the drug substance.These operations should be performed in closed systems, with minimal operator handling. Any aseptic operations performed by an operator(s) other than in a c
11、losed system should be identified and carefully reviewed.II. COMPONENTSIn addition to the impurity concerns for the manufacture of bulk drug substances, there is a concern with endotoxins in the manufacture of the sterile bulk drug substances. The validation report, which demonstrates the removal, i
12、f present, of endotoxins to acceptable levels, should be reviewed. Some manufacturers have commented that since an organic solvent is typically used for the conversion of the non-sterile bulk drug substance to the sterile bulk drug substance, that endotoxins will be reduced at this stage. As with an
13、y operation, this may or may not be correct. For example, in an inspection of a manufacturer who conducted extensive studies of the conversion (crystallization) of the non-sterile substance to the sterile drug substance, they found no change from the initial endotoxin level. Organic solvents were us
14、ed in this conversion. Thus, it is important to review and assess this aspect of the validation report.In the validation of this conversion (non-sterile to sterile) from an endotoxin perspective, challenge studies can be carried out on a laboratory or pilot scale to determine the efficiency of the s
15、tep. Once it is established that the process will result in acceptable endotoxin levels, some monitoring of the production batches would be appropriate. As with any validation process, the purpose and efficiency of each step should be evaluated. For example, if the conversion (crystallization) from
16、the non-sterile to the sterile substance is to reduce endotoxins by one log, then data should support this step.Since endotoxins may not be uniformly distributed, it is also important to monitor the bioburden of the non-sterile substance(s) being sterilized. For example, gram negative contaminats in a non-sterile bulk drug substance prior to sterilization are of concern, particularly if the sterilization (filtration) and crystallization steps do not reduce the end
